Key result
Oral P2Y12 inhibitor pre-treatment pathways in non-ST-elevation acute coronary syndromes are summarized according to evolving European Society of Cardiology guidelines.
Why the study?
Does oral P2Y12 inhibitor pre-treatment improve outcomes in patients with NSTE-ACS undergoing PCI?
Does oral P2Y12 inhibitor pre-treatment improve outcomes in patients with NSTE-ACS undergoing PCI?
This paper reviews the evolving recommendations in ESC guidelines regarding oral P2Y12 inhibitor pre-treatment for patients with NSTE-ACS undergoing PCI.
Answers are grounded in this paper and cite their sources.
Offers clinicians a guideline-aligned overview of P2Y12 pre-treatment in NSTE-ACS; leaves open optimal individualized strategies pending further evidence.
Oral P2Y12 inhibitor pre-treatment in non–ST-elevation acute coronary syndromes (NSTE-ACS). The upper portion summarizes the pre-treatment vs. no pre-treatment pathways. The classes of recommendation in the European Society of Cardiology guidelines as well as the acronyms of the main contributing studies are reported in the lower panel. *May include, among other, aortic dissection, pulmonary embolism, myopericarditis, and gastric ulcer. ACS, acute coronary syndrome; CABG, coronary artery bypass graft; CAD, coronary artery disease; DAPT, dual antiplatelet therapy; NSTEMI, non–ST-elevation myocardial infarction; P, prasugrel; PCI, percutaneous coronary intervention; T, ticagrelor; C, clopidogrel.
No takes yet. Share an insight, caveat, or question.
Roffi et al. (2024) conducted a review in non-ST-elevation acute coronary syndromes (NSTE-ACS). Oral P2Y12 inhibitor pre-treatment vs. no pre-treatment was evaluated. Oral P2Y12 inhibitor pre-treatment pathways in non-ST-elevation acute coronary syndromes are summarized according to evolving European Society of Cardiology guidelines.
Synapse has enriched 10 related papers. Consider them for comparative context: